下一代红细胞替代物。

Future generations of red blood cell substitutes.

作者信息

Chang T M S

机构信息

Artificial Cells & Organs Research Center, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

出版信息

J Intern Med. 2003 May;253(5):527-35. doi: 10.1046/j.1365-2796.2003.01151.x.

DOI:10.1046/j.1365-2796.2003.01151.x

PMID:12702030

Abstract

Polyhaemoglobins (PolyHb) and perfluorochemicals are in advanced phase III clinical trials and conjugated haemoglobins in phase II clinical trial. New recombinant human haemoglobin with no vasoactivity is being developed. A soluble macromolecule of PolyHb-catalase-superoxide dismutase is being studied as an oxygen carrier with antioxidant properties. New artificial red blood cells that are more like RBC are being developed. One is based on haemoglobin lipid vesicles. A more recent one is based on nano-dimension artificial red blood cells containing haemoglobin and RBC enzymes with membrane formed from composite copolymer of polyethylene glycol-polylactic acid. Their circulation time is double that of PolyHb.

摘要

多聚血红蛋白（PolyHb）和全氟化合物正处于III期临床试验后期，而共轭血红蛋白处于II期临床试验阶段。一种无血管活性的新型重组人血红蛋白正在研发中。一种具有抗氧化特性的多聚血红蛋白-过氧化氢酶-超氧化物歧化酶可溶性大分子正作为氧载体进行研究。更接近红细胞的新型人造红细胞正在研发中。一种基于血红蛋白脂质囊泡，另一种更新的则基于含有血红蛋白和红细胞酶的纳米尺寸人造红细胞，其膜由聚乙二醇-聚乳酸复合共聚物形成。它们的循环时间是多聚血红蛋白的两倍。